by MM360 Staff | Oct 7, 2020 | CME
Start Activity Activity Details Free CME/CNE/CPE 1.0 AMA PRA Category 1 Credit(s)™1 Contact Hour(s) 1 hour to complete Accredited By Rush University Medical Center Co-provided by Target Audience This activity is designed to meet the educational needs of hematologists,...
by MM360 Staff | Oct 7, 2020 | CME
Register Start Activity Join our new educational platform, HaemHQ, and participate in our upcoming meeting “Nurse Academy 1: How I Provide Care in ndMM” on Thursday 22nd October at 8:00 pm (AEDT). International and local multiple myeloma experts will share...
by MM360 Staff | Oct 7, 2020 | Featured News, Myeloma News
Chimeric antigen receptor (CAR) T cell therapy has shown remarkable successes in fighting B cell leukemias/lymphomas and numerous CAR-T’s are being developed for use in multiple myeloma. While primising results have been reported with BCMA CAR T cells, responses...
by MM360 Staff | Oct 6, 2020 | Featured News, Myeloma News
The success of T cell–mediated therapeutics depends, in part, on the selective expression of cell surface target epitopes to minimize the off-tissue toxicity. B-Cell Maturation Antigen (BCMA) is a protein that is selectively expressed on late-stage B cells and plasma...
by MM360 Staff | Oct 1, 2020 | Featured News, Myeloma News
Oncopeptides announced today that the Melflufen open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is formally open. EAPs are designed to provide patients living with serious or life-threatening conditions access to investigational medicines when...
